Edwards Lifesciences Co. (NYSE:EW – Get Rating) CEO Michael A. Mussallem sold 19,875 shares of the firm’s stock in a transaction that occurred on Tuesday, March 14th. The stock was sold at an average price of $77.61, for a total transaction of $1,542,498.75. Following the sale, the chief executive officer now owns 60,948 shares in the company, valued at approximately $4,730,174.28. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Edwards Lifesciences Trading Up 2.1 %
EW stock opened at $78.20 on Wednesday. The firm has a fifty day moving average price of $78.08 and a 200 day moving average price of $79.52. Edwards Lifesciences Co. has a fifty-two week low of $67.13 and a fifty-two week high of $131.10. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.17 and a current ratio of 3.03. The firm has a market cap of $47.57 billion, a PE ratio of 32.05, a price-to-earnings-growth ratio of 4.33 and a beta of 1.01.
Edwards Lifesciences (NYSE:EW – Get Rating) last posted its quarterly earnings data on Tuesday, January 31st. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.61 by $0.03. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.33 billion. Edwards Lifesciences had a net margin of 28.27% and a return on equity of 26.05%. Edwards Lifesciences’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.51 earnings per share. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.52 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the stock. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $92.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, January 6th. Wolfe Research cut shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 1st. Wells Fargo & Company cut shares of Edwards Lifesciences from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $97.00 to $78.00 in a research report on Wednesday, March 8th. Mizuho reduced their price objective on shares of Edwards Lifesciences from $100.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, December 7th. Finally, Sanford C. Bernstein cut shares of Edwards Lifesciences from an “outperform” rating to an “underperform” rating and reduced their price objective for the company from $95.00 to $66.00 in a research report on Tuesday, January 31st. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $88.95.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.
- Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.